D.E. Shaw & Co’s Ascendis Pharma A/S ASND Stock Holding History

D.E. Shaw & Co’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.38M	Sell	31,400 -16,700	-35%	-$3.9M	﹤0.01%	1979
2026 Q1	$11M	Buy	48,100 +42,400	+744%	+$9.5M	0.01%	1550
2025 Q4	$1.22M	Buy	5,700 +700	+14%	+$145K	﹤0.01%	3412
2025 Q3	$994K	Hold	5,000	–	–	﹤0.01%	3466
2025 Q2	$863K	Hold	5,000	–	–	﹤0.01%	3323
2025 Q1	$779K	Hold	5,000	–	–	﹤0.01%	3244
2024 Q4	$688K	Hold	5,000	–	–	﹤0.01%	3428
2024 Q3	$747K	Buy	+5,000	New	+$675K	﹤0.01%	3470

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

D.E. Shaw & Co's ASND Position: Q2 2026 in Review

D.E. Shaw & Co increased its Ascendis Pharma A/S (ASND) stake by 2,808% in Q2 2026, buying an estimated $6.97M and bringing the position to 30,883 shares worth $8.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1993.

D.E. Shaw & Co first reported a position in ASND in Q1 2018 and has held it in 34 quarters since. The position peaked at $51.4M in Q1 2024. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

D.E. Shaw & Co held 30,883 shares of Ascendis Pharma A/S worth $8.24M as of Q2 2026.
D.E. Shaw & Co bought 29,821 Ascendis Pharma A/S shares in Q2 2026, an estimated $6.97M.
Ascendis Pharma A/S made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1993 holding.
D.E. Shaw & Co first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 34 quarters since.
D.E. Shaw & Co's Ascendis Pharma A/S position peaked at $51.4M in Q1 2024.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.